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Appraisal

Appraisal of Clinical Practice Guideline: 2018 update of the EULAR
recommendations for the management of hand osteoarthritis
Date of latest update: August 2018. Date of next update: Not speciﬁed. Patient group: People
with hand osteoarthritis (OA). Intended audience: Not speciﬁed. Additional versions: European League Against Rheumatism (EULAR) hand OA guideline published in 2007. Expert
working group: The expert working group comprised one convenor, one methodologist, one
fellow, and a further task force of 10 rheumatologists, one plastic surgeon, three healthcare
professionals in the ﬁeld of physiotherapy and occupational therapy, two patient research
partners, and two Emerging EUlar NETwork (EMEUNET) members. Funded by: This clinical
practice guideline was funded by EULAR. Consultation with: No consultations beyond the
expert working group were speciﬁed. Approved by: The ﬁnal manuscript was reviewed,
revised and approved by all task force members, followed by a ﬁnal review by the EULAR
Executive Committee. Location: https://doi.org/10.1136/annrheumdis-2018-213826.
Description and key recommendations: The 2018 EULAR guidelines were developed to
update an existing guideline published in 2007 for the evidence-based management of hand
OA. The level of evidence and grade of evidence were computed regarding each recommendation, according to the Oxford Centre for Evidence-Based Medicine standards. According to
the results of this guideline, based on expert opinion and research evidence, ﬁve overarching
principles were agreed upon. These overarching principles were related to goals of treatment,
providing enough information to patients, individualising the treatment according to each
patient, shared decision-making, and having a multidisciplinary approach to hand OA

treatment, incorporating non-pharmacological, pharmacological and surgical treatment options. In addition to these ﬁve overarching principles,10 recommendations were also made by
the task force, as summarised in Table 1 of the guideline. The ﬁrst three recommendations are
related to the non-pharmacological treatment options for hand OA management. The next ﬁve
recommendations (recommendations 4 to 8) illustrate the role of pharmacological options for
treating hand OA, including topical treatments, oral analgesics, chondroitin sulfate, and intraarticular glucocorticoids (not recommended). Recommendations 9 and 10 focus on surgical
considerations and follow-up of the hand OA patients, respectively. A research agenda for hand
OA is created and presented in Table 2 of the guideline. This agenda covers different themes,
from pathophysiology to different treatment options for hand OA.
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Appraisal of Clinical Practice Guideline: Physiotherapy for cystic ﬁbrosis in
Australia and New Zealand
Date of latest update: 2019. Date of next update: Not stated. Patient group: People with
cystic ﬁbrosis in Australia and New Zealand. Intended audience: Physiotherapists. Additional versions: This guideline builds on a previous consensus statement published in 20081
and an evaluation of its uptake and impact published in 2013.2 The guideline can be accessed
as a published journal article,3 as well as an Executive Summary and Comprehensive Version
from the Thoracic Society of Australia and New Zealand website.4 Expert working group: All
physiotherapists providing regular care for people with cystic ﬁrobsis in paediatric or adult
settings in Australia or New Zealand were invited to participate. The ﬁnal expert working
group included: one chairperson, one editor, 12 group leaders and another 25 members,
who were all physiotherapists working with indivudals with cystic ﬁbrosis. Funded by:
The guidelines were partially funded by a grant from Cystic Fibrosis Australia. The prior
2008 consensus statement was partially funded by Roche Pharmaceuticals and Solvay
Pharmaceuticals. Consultation with: The draft document was reviewed by stakeholders,
including: physicians caring for people with cystic ﬁbrosis, people with cystic ﬁbrosis,
allied health professionals and expert physiotherapists who were not part of the writing
group. Approved by: The original 2008 consensus statement was endorsed by the
Thoracic Society of Australia and New Zealand. Chapters in the current clinical guidelines
were drafted by a writing group and circulated to the whole expert group for comment
and revision. The document was then compiled into one text by the editor and circulated
to the group for review. Location: Journal article: https://doi.org/10.1111/resp.12764;
Executive Summary and Comprehensive version: https://www.thoracic.org.au/journalpublishing/area?command=record&id=37. Description and key recommendations: The
2016 clinical practice guidelines were developed to update a 2008 consensus statement.
The aim was to optimise physiotherapy management of infants, children and adults with
cystic ﬁbrosis in Australia and New Zealand by standardising physiotherapy care and
providing a reference tool to support training of physiotherapists and isolated
practitioners. Recommendations were drawn from a systematic review of published
literature, relevant conference proceedings and stakeholder review. Recommendations
were formulated based on the quality, quantity and level of the evidence according to
National Health and Medical Research Council guidelines; the consistency of the body of
evidence; the likely clinical impact; and generalisability and applicability to physiotherapy
practice in Australia and New Zealand. Thirty recommendations were made across eight
domains of physiotherapy practice for children and adults with cystic ﬁbrosis, including:
airway clearance therapy (recommendations 1 to 5); inhalation therapy as an adjunct to
physiotherapy (recommendations 6 to 10); exercise assessment and training

(recommendations 11 to 15); musculoskeletal management (recommendations 16 to 18);
management of urinary incontinence (recommendations 19 to 21); managing the newly
diagnosed patient with cystic ﬁbrosis (recommendations 22 to 23); delivery of noninvasive ventilation (recommendations 24 to 28); and physiotherapy management before
and after lung transplantation (recommendations 29 to 30). These are summarised at the end
of each chapter. Elements of clinical practice that were considered important but lacked
research evidence were highlighted as 47 ‘Practice Points’. These provided additional information on the aforementioned practice areas, as well as the areas of: physiotherapy for
pregnancy, labour and the post-natal period (5 points); the transition from paediatric to adult
care (1 point); adherence to physiotherapy (3 points); infection control during physiotherapy
(7 points); and delivery of physiotherapy to inpatients and outpatients (3 points). The
guidelines conclude with 10 ‘Directions for future research’, which encourage research on:
effectiveness of individual respiratory techniques; combination of inhalation therapies with
physiotherapy techniques; effectiveness of exercise and strength training; management of
musculoskeletal complications; and optimal care for people with chronic respiratory failure.
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